# Jung Choi

> Jung Choi is the President and CEO of Alterome Therapeutics, a clinical-stage precision oncology company pioneering mutation-specific cancer drugs. With over 20 years in biopharmaceutical leadership - spanning Gilead Sciences, InterMune, Chimerix, and Global Blood Therapeutics where he led a $5.4B Pfizer acquisition - Choi brought deal-making, strategy, and operational depth to Alterome when he was appointed CEO in April 2025. Under his leadership, Alterome has advanced two first-in-class inhibitors into Phase 1/1b trials targeting KRAS and AKT1 E17K oncogenic drivers, backed by $231M in total funding including a $132M Series B.

- **Role:** President and CEO at Alterome Therapeutics, Inc.
- **Organizations:** Alterome Therapeutics, Inc., Annexon Biosciences (Board Member), New York Blood Center (Board Member), Marea Therapeutics (Board Member), California Life Sciences, Aspen Global Leadership Network, Center for Asian Health Research and Education (CARE), Stanford Medicine - Board of Advisors
- **Nationality:** American
- **Education:** Bachelor of Arts, Human Biology, Stanford University, MBA, Stanford University
- **Known for:** Led or managed over 50 transactions exceeding $17 billion in total value, As Chief Business & Strategy Officer at GBT, led the company from preclinical stage to full commercialization and the $5.4B acquisition by Pfizer (2022), Appointed as Aspen Institute Health Innovators Fellow (2019, fifth class)

## Career timeline

- **Early career** — Engagement Manager at McKinsey & Company (strategy consulting)
- **Mid career** — Vice President at Bay City Capital
- **~2004-2013** — Multiple roles at Gilead Sciences over 9 years: Director of Corporate Strategy, Head of Business Development, M&A, Director of Marketing (launched Hepsera)
- **—** — Senior Vice President, Corporate Development at Chimerix
- **—** — Senior Vice President, Corporate Development at InterMune - led integration during Roche/Genentech acquisition
- **~2016-2022** — Chief Business & Strategy Officer at Global Blood Therapeutics (GBT) - led $5.4B acquisition by Pfizer (October 2022)
- **2022-2025** — Entrepreneur-in-Residence at Third Rock Ventures
- **2025-04** — Appointed President and CEO of Alterome Therapeutics, Inc.

## Achievements

- Led or managed over 50 transactions exceeding $17 billion in total value
- As Chief Business & Strategy Officer at GBT, led the company from preclinical stage to full commercialization and the $5.4B acquisition by Pfizer (2022)
- Appointed as Aspen Institute Health Innovators Fellow (2019, fifth class)
- Member of the Aspen Global Leadership Network
- Oversaw Alterome advancing two first-in-class programs (ALTA3263 and ALTA2618) from inception to Phase 1/1b clinical trials in under four years
- Part of leadership team securing $231M total funding for Alterome, including $132M Series B led by Goldman Sachs Alternatives (April 2024)
- Named speaker at BIO International Convention 2026
- Board roles at Annexon Biosciences, New York Blood Center, and Marea Therapeutics

## Latest updates

- **2025-04** — Appointed President and CEO of Alterome Therapeutics, Inc., succeeding the previous leadership
- **2025-03** — Alterome dosed first patient in ALTA3263 (KRAS selective inhibitor) Phase 1/1b clinical trial
- **2025-01** — Alterome named one of Fierce Biotech's 2025 Fierce 15 companies
- **2024-04** — Alterome raised $132M Series B led by Goldman Sachs Alternatives (announced April 2024)

## Links

- Website: https://alterome.com
- LinkedIn: http://www.linkedin.com/in/jung-choi-9a40206
- Twitter/X: https://twitter.com/AlteromeTx

---

Profile page: https://yespress.io/jung-choi
Published by YesPress — https://yespress.io
Last updated: 2026-05-14